Moleculin Biotech special meeting: name change proposal fails; warrant issuance approved

Moleculin Biotech, Inc.

Stockholders rejected name change to Moleculin Inc.; needed majority of 36.7M outstanding shares but only 11.3M voted For.
Approved issuance of up to 64.9M shares upon exercise of warrants issued Aug 28, 2025 (4.9M For, 1.5M Against).
Adjournment proposal passed (5.6M For) to allow further proxy solicitation if needed.
Broker non-votes totaled 8.2M for warrants and adjournment proposals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.